Dec 27, 2021 / 01:00PM GMT
Operator
Good day, and welcome to the BridgeBio Pharma to discuss topline results from Phase III ATTRibute-CM study conference call. (Operator Instructions) As a reminder, this call is being recorded.
I would like to turn the call over to Neil Kumar, Founder and CEO of BridgeBio Pharma. You may begin.
Neil Kumar - BridgeBio Pharma, Inc. - Co-Founder, President, CEO & Director
Thank you, operator, and thank you all for the time. I'm sorry I don't have better news to share with everyone today. But Part A of our ATTRibute-CM trial did not meet its primary end point.
Although the drug, as we'll discuss, seemed to have performed as we would have hoped, the placebo arm of the trial, especially on 6-minute walk test, simply did not decline as compared with historical clinical trials or the natural history studies we reviewed. There was no real ability for our drug to show any signal against the measured baseline in the study to date.
Before I continue, I'd like to acknowledge the disappointment many of you are feeling right now, for the patients
BridgeBio Pharma Inc to Discuss Topline Results from Phase 3 Attribute-CM Study Call Transcript
Dec 27, 2021
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers